

**CME INFORMATION**  
**2022 NEW YORK TRANSCATHETER VALVES SYMPOSIUM**  
DECEMBER 8, 2022

**Target Audience**

The New York Valves Symposium has been designed to meet the educational needs of interventional cardiologists, invasive cardiologists, cardiothoracic surgeons, interventional radiologists, interventional fellows-in-training, nurses, technicians, and allied health care professionals who work in structural heart disease.

**Educational Goal**

The purpose of this activity is to provide participants with the latest updates in diagnostic and treatment strategies of structural heart disease.

**Learning Objectives**

- Evaluate new and upcoming technologies in the management of structural heart disease
- Explain indications, techniques, outcomes, and complications for transcatheter valve intervention in patients with native valve disease and bioprosthetic valve dysfunction
- Evaluate the rationale, challenges, and necessity of the heart team approach to valvular heart disease, appropriate case selection for transcatheter mitral and tricuspid valve repair
- Assess the barriers to care in patients with valvular heart disease with specific attention to current gaps in the timely delivery of percutaneous and surgical interventions

**Accreditation**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of *CMEsolutions* and Gaffney Events. The *CMEsolutions* is accredited by the ACCME to provide continuing medical education for physicians.

The *CMEsolutions* designates this live activity for a maximum of **7 AMA PRA Category 1 Credits.**<sup>™</sup> Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component and 75% passing on MOC test, enables the participant to earn up to 7 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**Nursing Contact Hour Information**

This nursing continuing professional development activity was approved by Montana Nurses Association, an accredited approver with distinction by the American Nurses Credentialing Center's Commission on Accreditation. 6.5 contact hours

**ASRT**

ASRT – 7.75 Category A Credits

## **FEES**

There are fees for participating in this activity as explained on the website.

## **PARTICIPATION REQUIREMENTS**

1. Read CME Information
2. Attend/Participate in Sessions - credit given commensurate with attendance
3. Beginning **Friday, December 9<sup>th</sup>**, complete the course evaluation and credit request form at: <https://online-med-edu.com/nytv/1282022/> and download or print credit statement
4. MOC credit will appear in your ABIM account four weeks after successful completion of your request

**NOTE: ABIM MOC II points for NYTV can only be claimed until January 7, 2023.**

## **FACULTY AND DISCLOSURES**

*CMEsolutions* requires everyone in a position to control the content of this activity to disclose any relevant financial conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by *CMEsolutions* for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. *CMEsolutions* has mitigated all conflicts of interest prior to this educational activity.

### **Alexandre Abizaid, MD, PhD, FACC**

Director of Invasive Cardiology, Instituto do Coração (Incor) at the University of São Paulo  
São Paulo, Brazil

*Disclosed the following relevant financial relationship: Boston Scientific-Proctor*

### **David H. Adams, MD**

Cardiac Surgeon-in-Chief, Department of Cardiovascular Surgery, Mount Sinai Health System  
New York, NY

*Disclosed the following relevant financial relationships: Medtronic- National Co-PI of the Medtronic APOLLO FDA Pivotal Trial and The Medtronic CoreValve US Pivotal Trial; NeoChord- National Co PI NeoChord FDA Pivotal Trial; Abbott- National Co PI TRILUMINATE Pivotal Trial*

### **Robert O. Bonow, MD**

Professor of Cardiology, Northwestern University  
Chicago, IL

*Has no relevant financial relationships to disclose.*

### **Joanna Chikwe, MD, FRCS, FACC**

Editor-in-Chief, The Annals of Thoracic Surgery; Chairman, Department of Cardiac Surgery, Irina and George Schaeffer Distinguished Professor, Cedars-Sinai Health System  
Los Angeles, CA

*Has no relevant financial relationships to disclose.*

### **Antonio Colombo, MD, FACC, MSCAI**

Director, Cardiac Catheterization Laboratory, EMO GVM Centro Cuore Columbus, Humanitas Research Hospital,  
Milan, Lombardia, Italy

*Has no relevant financial relationships to disclose.*

**George D. Dangas, MD, PhD, MACC, MSCAI**

Professor of Cardiology & Vascular Surgery Director, Cardiovascular Innovation, The Mount Sinai Hospital  
New York, NY

*Has no relevant financial relationships to disclose.*

**Eberhard Grube, MD, MSCAI**

Head CIIC, University Hospital Bonn  
Bonn, Germany

*Disclosed the following relevant financial relationships: Medtronic, Boston Scientific, HighLife, Jena Valve, Protembis-Speaker's Bureau/SAB*

**Howard C. Herrmann, MD, MSCAI**

Bryfogle Professor of Medicine; System Director and Section Chief, Interventional Cardiology, University of Pennsylvania  
Philadelphia, PA

*Disclosed the following relevant financial relationships: Abbott, Boston Scientific, Edwards Lifesciences, Medtronic-Institutional Research Funding; Edwards Lifesciences, Medtronic-Consultant*

**Amit Hooda, MD, FACC**

Assistant Professor, Department of Medicine, Cardiology, Icahn School of Medicine at Mount Sinai  
New York, NY

*Has no relevant financial relationships to disclose.*

**Saibal Kar, MD, FACC**

Director of Structural Heart Disease Interventions Physician Director, Interventional Cardiology, HCA Healthcare,  
Los Robles Regional Medical Center  
Los Angeles, CA

*Disclosed the following relevant financial relationships: Abbott, Boston Scientific, WL Gore – Consultant; Medtronic- Consultant, Proctor*

**Sahil Khera, MD, MPH, FACP, FACC, FSCAI**

Interventional Director, Structural Heart Program, The Mount Sinai Hospital  
New York, NY

*Disclosed the following relevant financial relationships: Medtronic – Consultant, Speaker, Proctor; Terumo, Abbott, EastEnd Medical – Consultant; Zoll – Speaker*

**Annapoorna S. Kini, MD, MRCP, FACC**

Interventional Director, Structural Heart Program, Mount Sinai Health System; Director, Cardiac Catheterization Laboratory; Zena and Michael A. Wiener Professor of Medicine, The Mount Sinai Hospital  
New York, NY

*Has no relevant financial relationships to disclose.*

**Parasuram Krishnamoorthy, MD, FACC, FSCAI**

Associate Director, Structural Heart Program Assistant Professor of Medicine, Division of Cardiology, Icahn School of Medicine at Mount Sinai  
New York, NY

*Has no relevant financial relationships to disclose.*

**Stamatios Lerakis, MD, PhD, FACC, FAHA**

Director of Noninvasive Cardiology and Structural Echocardiography; Professor of Medicine, Cardiology, The Mount Sinai Hospital

New York, NY

*Has no relevant financial relationships to disclose.*

**Roxana Mehran, MD, FACC, FACP, FAHA, FCCP, FESC, MSCAI**

Director, Interventional Cardiovascular Research and Clinical Trials; Professor of Medicine, Cardiology; Professor of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai

New York, NY

*Disclosed the following relevant financial relationships: Cine-Med, WebMD-Consultant*

**Michael J. Reardon, MD, FACC**

Professor of Cardiothoracic Surgery; Allison Family Distinguished Chair of Cardiovascular Research; Surgical Director of Structural Heart Disease, Houston Methodist DeBakey Heart & Vascular Center

Houston, TX

*Has no relevant financial relationships to disclose.*

**Arthur B. Reitman, MD, FACC**

Chief, Inpatient Cardiology Services, Wellstar Health Systems

Atlanta, GA

*Has no relevant financial relationships to disclose.*

**Samin K. Sharma, MD, FACC, MSCAI**

Director, Mount Sinai Cardiovascular Clinical Institute; Director, Interventional Cardiology, Mount Sinai Health System; Anandi Lal Sharma Professor of Medicine, Cardiology, The Mount Sinai Hospital

New York, NY

*Disclosed the following relevant financial relationships: Abbott, Boston Scientific, Cardiovascular Systems, Inc.-Speaker's Bureau*

**Lars Sondergaard, MD**

Professor of Cardiology, Rigshospitalet

Copenhagen, Denmark

*Has no relevant financial relationships to disclose.*

**Gregg W. Stone, MD, FACC, MSCAI**

Director of Academic Affairs for the Mount Sinai Heart Health System; Professor of Medicine, Cardiology; Professor of Population Health Sciences and Policy, Mount Sinai Health System

New York, NY

*Disclosed the following relevant financial relationships: Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical, Millennia Biopharma, CorFlow, Apollo Therapeutics, Cardiomech, Amgen-Consultant; Medtronic, Pulnovo, Infraredx, Abiomed-Speaker; Abbott, Shockwave, Vascular Dynamics, Pulnovo, Phillips, Cardiovascular Systems Inc., Biosense Webster, Bioventrix, V-wave-Institutional Research Grants*

**Gilbert Tang, MD, MSc, MBA, FACC, FSCAI**

Surgical Director, Structural Heart Program; Professor of Cardiovascular Surgery, Mount Sinai Health System

New York, NY

*Disclosed the following relevant financial relationships: Abbott Structural Heart-Consultant, Advisory Board; Medtronic-Proctor, Consultant; JenaValve-Advisory Board; NeoChord-Consultant; Siemens Healthineers-Speaker*

**Dee Dee Wang, MD, FACC, FASE, FSCCT, FSCAI**

Director, Structural Heart Imaging. Medical Director of 3D Printing, Henry Ford Health System, Henry Ford Innovation Institute  
Detroit, MI

*Disclosed the following relevant financial relationships: Edwards Lifesciences, Abbott, Materialise-Consultant; Boston Scientific-Research Grant support assigned to employer Henry Ford Health*

**David A. Wood, MD, FRCPC, FACC, FESC, FSCAI**

Director, CCI-CIC/Head, Division of Cardiology, VGH, VGH & UBC Division of Cardiology  
Vancouver, British Columbia, Canada

*Disclosed the following relevant financial relationships: Edwards Lifesciences, Abbott, Medtronic-Research Grant*

**Planner Disclosures**

No member of *CMEsolutions* or Gaffney Events has any relevant financial relationships to disclose regarding this activity.

**Off-label Use**

This activity may contain discussion of unlabeled and/or investigational uses of agents not approved by the FDA. Please consult the prescribing information for each product.

**Commercial Support**

Commercial Support for this activity is provided by the following:

- Abbott
- Boston Scientific
- Edwards Lifesciences
- Medtronic

**Privacy Policy**

*CMEsolutions* Privacy and Confidentiality Policy: [www.online-med-edu.com/privacypolicy.pdf](http://www.online-med-edu.com/privacypolicy.pdf)

*CMEsolutions* can be contacted at [info@cmesolutions.org](mailto:info@cmesolutions.org).